JNJ
$258.45+1.44%
as of close, Oct 7, 2026
☾ AH $258.45 +1.44%
Johnson & JohnsonStock · HealthcareDow Jones 2.9%S&P 500 0.9%Russell 1000 0.9%US Stock Market 0.8%Russell 3000 0.8%MSCI ACWI 0.6%MSCI World 0.6%S&P 500 Equal Weight 0.2%
JNJ — Johnson & Johnson price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDED
120.0140.0160.0180.0200.0220.0240.0260.00200.0M400.0M$258.45—20162019202120242026
2026-10-07
Price$258.45
MA20$251.24
MA50$225.41
Vol31.9M
Key stats#
Price data
- Price
- $258.45
- YTD price return
- +24.89%
- YTD total return
- +26.89%
- Next earnings
- Oct 13, 2026 · Before open
- Market cap
- 622.8B
- Enterprise value
- 652.5B
- Shares outstanding
- 2.4B
- 52W low
- $182.94
- 52W high
- $281.07
- From 52W high
- -8.05%
- From 52W low
- +41.28%
- 52W range
- 77%
- Beta
- 0.24
Volume
- Rel volume
- 0.79×
- 30D volume
- 6.7M
- 30D $ vol
- 1.8B
Insider trading
- Insider net 1W
- none
- Insider net 1M
- none
- Insider net 3M
- −$67.8M
- Insider net 1Y
- −$150.7M
Form 4 transactions by trade date, as filed; latest on file 2026-09-02.
Fundamentals
- Sales (ttm)
- 97.9B
- Sales/share
- $40.64
- EPS (ttm)
- $8.62
- FCF (ttm)
- 22.2B
- FCF/share
- $9.23
- Book value/share
- $35.26
- Net margin
- 21.48%
- ROE
- 24.76%
- ROA
- 10.46%
- Debt / equity
- 0.44×
- Current ratio
- 1.09
Growth (CAGR, ttm) · 10Y
- Sales
- +8.09%+5.97%+1.89%+3.31%
- Net income
- -7.19%+17.31%+3.45%+3.43%
- FCF
- +20.00%+15.26%-0.29%+4.43%
- Shares
- +0.06%-2.49%-1.76%-1.26%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -7.74%+20.49%+5.35%+4.86%
- Sales/share
- +8.02%+8.68%+3.72%+4.61%
- FCF/share
- +19.92%+18.21%+1.50%+5.77%
- Book value/share
- +8.24%+6.86%+5.95%+2.91%
- Dividend/share
- +4.40%+4.61%+5.10%+5.57%
- Price
- +36.86%+17.89%+9.88%+8.09%
- Total return
- +39.94%+21.29%+13.00%+11.06%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 30.0×
- P/OI (ttm)
- 28.6×
- Fwd P/E
- 21.1×
- P/S (ttm)
- 6.4×
- P/B (mrq)
- 7.3×
- P/FCF (ttm)
- 28.0×
- EV/EBITDA (fy)
- 19.2×
- EV/Sales (ttm)
- 6.7×
- FCF yield (ttm)
- 3.57%
- Dividend yield (fwd)
- 2.07%
- Dividend yield (ttm)
- 2.04%
- Dividend/share (fwd)
- $5.36
- Buyback yield (realized, 1y)
- -0.06%
- Shareholder yield (realized, 1y)
- 3.38%
- Buyback yield (cash, ttm)
- 1.30%
- Shareholder yield (cash, ttm)
- 3.32%
Vs own 10Y history
- P/E
- 82nd
- P/OI
- 98th
- P/S
- 96th
- P/B
- 98th
- P/FCF
- 92nd
Bar = where today’s multiple sits in JNJ’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-07#
1D
+1.44%
5D
-2.38%
1M
-6.10%
3M
-3.29%
YTD
+24.89%
1Y
+36.83%
5Y
+60.19%
Recent filings#
- Sep 2Insider sale · Schmid Timothy (EVP, WW Chair, MedTech) sold 33,597 shares for $9.2M at $274.74
- Aug 17Insider sale · Taubert Jennifer L (EVP, WWC. Innovative Medicine) sold 15,000 shares for $4.0M at $263.36
- Aug 13Insider sale · Duato Joaquin (CEO and Chairman of the Board · Director) sold 171,771 shares for $44.7M on 2 days since Aug 5
- Aug 6Insider sale · Forminard Elizabeth (EVP, Chief Legal Officer) sold 15,918 shares for $4.1M at $255.93–$257.76
- Aug 48-K · Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
Financial statements
Open full JNJ financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +3.42% | +2.70% |
| ABBV | AbbVie Inc. | +5.81% | +1.75% |
| MRK | Merck & Co. Inc. | -5.02% | +0.60% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -5.33% | -0.09% |
| TMO | Thermo Fisher Scientific Inc. | +7.87% | +0.83% |
| AMGN | Amgen Inc. | -5.52% | +2.60% |
| GILD | Gilead Sciences Inc. | -2.75% | +1.82% |
| ABT | Abbott Laboratories | -8.86% | +0.58% |
